Cargando…

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

Estrogen receptor (ER)-positive breast cancer is the main subtype of breast cancer (BRCA) with high incidence and mortality. Andrographolide (AD), a major active component derived from the traditional Chinese medicine Andrographis paniculate, has substantial anti-cancer effect in various tumors. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Tong, Jiang, Yanyu, Yuan, Shuying, Zhang, Li, Chen, Xihui, Zhao, Weili, Cai, Lili, Xiao, Biying, Jia, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124841/ https://www.ncbi.nlm.nih.gov/pubmed/35615146 http://dx.doi.org/10.3389/fonc.2022.899402

Ejemplares similares

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
por: Finnegan, Ryan M., et al.
Publicado: (2023)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

Apigenin Inhibits the Histamine-Induced Proliferation of Ovarian Cancer Cells by Downregulating ERα/ERβ Expression
por: Liu, Manman, et al.
Publicado: (2021)

HOXA1 Is an Antagonist of ERα in Breast Cancer
por: Belpaire, Magali, et al.
Publicado: (2021)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Daurisoline Inhibits ESCC by Inducing G1 Cell Cycle Arrest and Activating ER Stress to Trigger Noxa-Dependent Intrinsic and CHOP-DR5-Dependent Extrinsic Apoptosis via p-eIF2α-ATF4 Axis
por: Yuan, Shuying, et al.
Publicado: (2022)

ER stress as a trigger of UPR and ER-phagy in cancer growth and spread
por: Cherubini, Alessandro, et al.
Publicado: (2022)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Spoerke, Jill M., et al.
Publicado: (2016)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Andrographolide is an Alternative Treatment to Overcome Resistance in ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway
por: Rajaratinam, Harishini, et al.
Publicado: (2019)

Regulation of ERα Stability and Estrogen Signaling in Breast Cancer by HOIL-1
por: Ding, Jianing, et al.
Publicado: (2021)

Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
por: Wang, Guangdi
Publicado: (2020)

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
por: Zheng, Zao-zao, et al.
Publicado: (2022)

Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling
por: Pham, Thu Ha, et al.
Publicado: (2021)

microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer
por: Gao, Shan, et al.
Publicado: (2020)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
por: Fox, Emily M., et al.
Publicado: (2012)

The Novel Curcumin Derivative 1g Induces Mitochondrial and ER-Stress-Dependent Apoptosis in Colon Cancer Cells by Induction of ROS Production
por: Wang, Hao, et al.
Publicado: (2021)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
por: Millour, Julie, et al.
Publicado: (2010)

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
por: Millour, J, et al.
Publicado: (2010)

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
por: Sharma, Vikas, et al.
Publicado: (2022)

ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2
por: Wang, Chunyan, et al.
Publicado: (2021)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer
por: Ni, Wenting, et al.
Publicado: (2021)

Increased reactive oxygen species levels cause ER stress and cytotoxicity in andrographolide treated colon cancer cells
por: Banerjee, Aditi, et al.
Publicado: (2017)

Deciphering of a Putative GPER Recognition Domain in ERα and ERα36
por: Acramel, Alexandre, et al.
Publicado: (2022)

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER(+) Breast Cancer
por: Ros, Susana, et al.
Publicado: (2020)

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism
por: Edavana, Vineetha K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_94lmv5qlo81t507vo2bs36lt1s